OBJECTIVE — Randomized treatment comparing an intensive glycemic treatment strategy with a standard strategy in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was ended early because of an unexpected excess of mortality in the intensive arm. As part of ongoing post hoc analyses of potential mechanisms for this finding, we explored whether on-treatment A1C itself had an independent relationship with mortality.

RESEARCH DESIGN AND METHODS — Participants with type 2 diabetes (n = 10,251) with mean age 62 years, median diabetes duration 10 years, and median A1C 8.1% (standard) were randomly assigned to treatment strategies targeting either A1C <6.0% (intensive) or A1C 7.0–7.9% (standard). Data obtained during 3.4 (median) years of follow-up before cessation of intensive treatment were analyzed using several multivariable models.

RESULTS — Various characteristics of the participants and the study sites at baseline had significant associations with the risk of mortality. Before and after adjustment for these covariates, a higher average on-treatment A1C was a stronger predictor of mortality than the A1C for the last interval of follow-up or the decrease of A1C in the first year. Higher average A1C was associated with greater risk of death. The risk of death with the intensive strategy increased approximately linearly from 6–9% A1C and appeared to be greater with the intensive than with the standard strategy only when average A1C was >7%.

CONCLUSIONS — These analyses implicate factors associated with persisting higher A1C levels, rather than low A1C per se, as likely contributors to the increased mortality risk associated with the intensive glycemic treatment strategy in ACCORD.

Type 2 diabetes is associated with increased risk of cardiovascular events (1–3) in part because hypertension, dyslipidemia, and other risk factors are associated with diabetes. Epidemiological analyses also suggest that each 1% higher A1C is associated with 15–20% greater cardiovascular risk (4–7). The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was designed to test whether intensive intervention to control hyperglycemia to a nearly normal range in patients with type 2 diabetes can reduce cardiovascular risks (8–10). It also included randomized comparisons of two targets for blood pressure control and two regimens for control of plasma lipid levels.

The aim of an intensive glycemic strategy was to reduce A1C to <6.0%, whereas the aim of a standard strategy was for a more conventional target range (10). Because of an unexpected finding, the intensive treatment strategy was discontinued early, after 3.4 years (median) rather than the planned 5.6 years of follow-up. All-cause mortality was greater with the intensive strategy (1.4 vs. 1.1% per patient-year [257 vs. 203 total deaths during follow-up], resulting in a hazard ratio [HR] of 1.22, P = 0.04). Initial analyses did not identify any specific cause for this finding (11). Several potential mechanisms have been suggested, including hypoglycemia, weight gain, and individual drugs, drug combinations, or drug dosages (12–14). In addition, the effects of rapid lowering of glucose levels or maintenance of nearly normal levels are of great interest. Although the ACCORD trial compared treatment strategies rather than actual levels of A1C, the question arises whether A1C values <7% may, independent of other circumstances, pose an unacceptable risk of death for any high-risk person with type 2 diabetes. To clarify this relationship between glycemic control and mortality, we performed post hoc analyses using data obtained at baseline and during randomized treatment.

RESEARCH DESIGN AND METHODS — The rationale, study design, and entry criteria for the ACCORD trial are described elsewhere (8–10). The ACCORD trial was conducted at 77 clinical sites in the U.S. and Canada. Between January 2001 and October 2005, 10,251 participants with type 2 diabetes and either a prior cardiovascular event or other evidence of high risk were enrolled.
They were randomly assigned to either an intensive glycemic strategy with the aim of achieving A1C <6.0% or a standard strategy with the aim of keeping A1C between 7.0 and 7.9%. Any antihyperglycemic agents approved by regulatory authorities could be used, as considered appropriate for each individual by investigators at the clinical sites, together with lifestyle interventions. The ACCORD formulation provided, free of cost to participants, at least one agent in each of the major categories of antihyperglycemic drugs. In addition, in a double two-by-two factorial design, all participants were enrolled in either a blood pressure trial comparing an intensive with a standard treatment strategy or a lipid trial comparing treatment with fenofibrate versus placebo while maintaining good control of LDL cholesterol, mainly with simvastatin. The primary end point of all components of the ACCORD trial is a composite of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. All-cause mortality is a predefined secondary end point.

The intensive glycemic treatment strategy was stopped in February 2008. The dataset used for the present analyses comprises findings for all randomized participants from enrollment until 10 December 2007. Of the 10,251 participants in the ACCORD trial, 5,123 were randomly assigned to standard and 5,128 to intensive glycemic management.

Participants visited clinical sites every 2–4 months. At the 4-month intervals, they were asked about hypoglycemia and other medical events, were weighed, and had blood collected for A1C measurements.

Statistical analysis
Four ways of assessing each participant’s glycemic levels were used. First, the overall glycemic exposure during randomized treatment was defined as a time-varying covariate of the mean of all 4-month A1C values after the baseline measurement to the end of the period covered in this dataset or until the time of death. This was called the average A1C. Second, a time-varying measure reflecting glycemic control just before each measurement was also used. This was termed the last A1C. Third, the magnitude of the early reduction of glucose levels was assessed as a time-varying covariate by subtracting the mean of A1C values in the first 12 months after initiation of glycemic treatment for each participant from the baseline value. For the first 4 months, the 0- to 4-month decrease was used, for months 4–8, the difference between baseline and the average of 4 and 8 months was used; and for months 8 and onward the difference between baseline and the average of months 4, 8, and 12. This was the 1-year decrease in A1C. Finally, the earliest changes in A1C were examined by computing 0- to 4-month decreases from baseline. This was the 4-month decrease in A1C.

Potential confounders of interpretation of the relationships between time-varying measures of A1C and occurrence of mortality from any cause included characteristics of the participants at baseline, characteristics of the clinical site at which an individual was enrolled, and selected factors related to the randomization or postrandomization experience (Table 1). Study site characteristics included the number of participants enrolled, whether the site was part of an integrated health plan, whether the principal investigator was a diabetes specialist, and whether a full-time certified diabetes educator was part of the staff.

Postrandomization factors (not shown in Table 1) included incidence of hypoglycemia requiring medical assistance and weight gain or loss. Hypoglycemia requiring medical assistance was defined as a time-varying covariate of self-report of hypoglycemic symptoms requiring assistance by medical personnel on at least one occasion before death or completion of the period of treatment. The time-varying covariate is 0 until a hypoglycemic episode and 1 thereafter. Weight change from baseline was defined as a time-varying covariate and divided into loss of weight >5 kg, gain of ≥5 kg, and gain or loss of up to 5 kg. Factors introduced at randomization included participation in the blood pressure or lipid trial, assignment to intensive blood pressure treatment, and assignment to fenofibrate treatment (15,16). Inclusion in these treatment groups is not presented here but is included in the modeling procedure.

Unadjusted relationships of these factors with all-cause mortality were examined to identify potentially confounding variables using Cox proportional hazard models with Wald confidence intervals and tests. Factors with univariate relationships with P < 0.25 were used in a model selection procedure. Backwards, forwards, and stepwise approaches resulted in the same models. Baseline A1C was included in all models. Model 1 included the selected characteristics of the participants and their sites at baseline. Model 2 added severe hypoglycemia and weight change as time-varying covariates and the randomization assignments in other ACCORD trials. Model 3 included the components of model 2 plus assignment to the standard or intensive glycemic treatment strategies. Curves modeling the relationships over the range of observed A1C values (penalized B-splines) (17,18) were used to explore the linearity assumption in the Cox proportional hazards model. Figure 1 presents the linear portion of the Cox proportional hazards model. Figure 1 presents the linear portion of the Cox proportional hazards model [\( h(t) = h(0)e^{\beta'x(t)} \)]. Tests of linearity of the effect of average A1C were performed by comparing models with linear terms with those with spline terms using likelihood ratio tests. Testing for differences of the nonlinear fits between intensive and standard glycemia assignment was done by comparing the nested models with one spline (same for both groups) and two splines (allowing different fits), also with likelihood ratio tests. Finally, Poisson regression provided direct estimates of mortality rates in relation to the magnitude of the 1-year change of A1C.

RESULTS

Patterns of glycemic control and mortality in the intensive and standard treatment groups
A1C values declined rapidly from the 8.1% (median) baseline in both treatment groups in the 1st year of treatment. With standard treatment, a plateau value close to 7.5% was maintained thereafter. With intensive treatment a plateau at 6.4% was established between 12 and 24 months. All-cause mortality rates were equivalent with the two strategies in the first 2 years, but in the 3rd year the rate with the intensive strategy was twice that with the standard strategy (supplementary Figure A1, available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc09-1278/DC1).

Average on-treatment A1C showed substantial overlap for individuals in the two groups (supplementary Figure A2). With the intensive strategy, average A1C was ≤6% at 4.4% of the participants’ visits, between 6.0 and <7.0% at 55.1%, and ≥7.0% at 40.5%. With the standard strategy, corresponding values were 0.2, 9.0, and 90.8%. Deaths from both cardiovascular and noncardiovascular causes occurred over a wide range of A1C values with both treatment strategies, with considerable overlap between the strategies. Approximately half of the deaths were due to cardiovascular causes (135 of 257 deaths).
Table 1—Characteristics of the study population at baseline and of the study sites at which they were enrolled, with univariate HRs for all-cause mortality

| Baseline characteristic                                      | Value       | HR (95% CI)          | P value | Overall P value |
|--------------------------------------------------------------|-------------|----------------------|---------|-----------------|
| Age (years)                                                  | 62.2 ± 6.8  | 1.08 (1.06–1.09)     | <0.0001 |                 |
| Female                                                       | 3,952 (38.6)| 0.64 (0.52–0.78)     | <0.0001 |                 |
| Race/ethnicity                                               |             |                      | 0.001   |                 |
| African-American                                            | 1,952 (19)  | 0.81 (0.63–1.03)     | 0.0821  |                 |
| Hispanic                                                    | 738 (7.2)   | 0.71 (0.47–1.06)     | 0.09    |                 |
| Other                                                       | 1,117 (10.9)| 0.51 (0.35–0.74)     | 0.0004  |                 |
| Non-Hispanic white                                          | 6,444 (62.9)|                      | 1       |                 |
| Diabetes duration                                           |             |                      | 0.002   |                 |
| 6–10 years                                                  | 2,931 (29.3)| 0.88 (0.68–1.14)     | 0.3,422 |                 |
| 11–15 years                                                 | 1,958 (19.6)| 0.86 (0.64–1.15)     | 0.3,041 |                 |
| ≥16+ years                                                  | 2,341 (23.4)| 1.33 (1.05–1.7)      | 0.0203  |                 |
| ≤5 years                                                    | 2,776 (27.7)|                      | 1       |                 |
| History of cardiovascular disease                           | 3,608 (35.2)| 2.07 (1.72–2.48)     | <0.0001 |                 |
| Prior myocardial infarction                                 | 475 (4.6)   | 1.44 (0.99–2.09)     | 0.0592  |                 |
| Heart failure/congestive heart failure                      | 494 (4.9)   | 3.18 (2.42–4.17)     | <0.0001 |                 |
| Retinal surgery                                              | 879 (8.6)   | 1.67 (1.28–2.17)     | 0.0001  |                 |
| Amputation                                                   | 185 (1.8)   | 2.64 (1.71–4.09)     | <0.0001 |                 |
| Education                                                   |             |                      | 0.0028  |                 |
| Less than high school                                       | 1,521 (14.8)| 1.64 (1.23–2.19)     | 0.0007  |                 |
| High school graduate                                        | 2,704 (26.4)| 1.42 (1.1–1.85)      | 0.0079  |                 |
| Some college                                                | 3,357 (32.8)| 1.18 (0.91–1.53)     | 0.218   |                 |
| College graduate or more                                    | 2,662 (26)  |                      | 1       |                 |
| Smoking                                                     |             |                      | <0.0001 |                 |
| Former                                                      | 4,527 (44.2)| 1.78 (1.44–2.21)     | <0.0001 |                 |
| Current                                                     | 1,429 (14)  | 2.13 (1.62–2.8)      | <0.0001 |                 |
| Never                                                       | 4,282 (41.8)|                      | 1       |                 |
| Alcohol use                                                 |             |                      | 0.0589  |                 |
| 1–6 drinks/week                                             | 1,975 (19.3)| 0.75 (0.59–0.97)     | 0.0282  |                 |
| 7+ drinks/week                                              | 470 (4.6)   | 1.15 (0.76–1.72)     | 0.5,065 |                 |
| No drinks/week                                              | 7,801 (76.1)|                      | 1       |                 |
| Insulin use                                                 | 3,579 (34.9)| 1.4 (1.17–1.69)      | 0.0003  |                 |
| ACE inhibitor                                               | 5,433 (53)  | 1.27 (1.05–1.52)     | 0.0131  |                 |
| Angiotensin receptor blockers                               | 1,639 (16)  | 0.79 (0.59–1.04)     | 0.0928  |                 |
| Statins                                                     | 6,363 (62.1)| 0.92 (0.76–1.1)      | 0.3534  |                 |
| Metformin                                                   | 6,135 (59.8)| 0.84 (0.7–1.01)      | 0.0665  |                 |
| Secretagogues                                               | 5,273 (51.4)| 0.79 (0.66–0.95)     | 0.0105  |                 |
| Thiazolidinediones                                          | 1,982 (19.3)| 0.85 (0.67–1.09)     | 0.204   |                 |
| BMI (kg/m²)                                                 | 32.2 ± 5.5  | 1 (0.984–1.017)      | 0.9773  |                 |
| Systolic blood pressure (mmHg)                              | 136.4 ± 17.1| 1.003 (0.997–1.008)  | 0.3316  |                 |
| Diastolic blood pressure (mmHg)                             | 74.9 ± 10.7 | 0.975 (0.966–0.984)  | <0.0001 |                 |
| Visual acuity                                               |             |                      | <0.0001 |                 |
| <20/40                                                      | 2,337 (23.9)| 3.36 (2.26–5)        | <0.0001 |                 |
| 20/20–20/40                                                 | 5,948 (60.7)| 2.16 (1.47–3.18)     | <0.0001 |                 |
| ≥20/20                                                      | 1,510 (15.4)|                      | 1       |                 |
| Peripheral neuropathy                                       | 4,356 (42.6)| 1.83 (1.52–2.2)      | <0.0001 |                 |
| Heart rate                                                  | 72.7 ± 11.8 | 1 (0.992–1.008)      | 0.9311  |                 |
| Q-T index                                                   | 101.8 ± 5.2 | 1.05 (1.03–1.06)     | <0.0001 |                 |
| A1C (%)                                                     | 8.3 ± 1.1   | 1.04 (0.96–1.14)     | 0.3252  |                 |
| Fasting plasma glucose (mg/dl)                              | 175.3 ± 56.2| 1 (0.998–1.001)      | 0.6445  |                 |
| LDL (mg/dl)                                                 | 104.9 ± 33.9| 0.998 (0.995–1.001)  | 0.119   |                 |
| HDL (mg/dl)                                                 | 41.9 ± 11.6 | 0.988 (0.98–0.996)   | 0.0054  |                 |
| Triglycerides (mg/dl)                                       | 190.1 ± 148.4| 1 (0.999–1.001)     | 0.9412  |                 |
with the intensive strategy and 109 of 203 with the standard strategy).

**Characteristics of the participants and study sites and relationships with mortality**

Table 1 shows the composition of the study population and the unadjusted relationships between all-cause mortality and baseline characteristics of the participants and their study sites.

**Associations between A1C and mortality without and with adjustment for characteristics of the participants and study sites and selected postrandomization events**

Results of the proportional hazards regression models adjusting for the effects of potentially confounding variables are summarized in Table 2. Of the three A1C measures, average A1C had the strongest association with mortality. A 1% higher average A1C was associated with HRs of 1.20 (P = 0.0002) unadjusted, 1.22 (P = 0.0001) after adjustment for baseline, site-related, and some postrandomization factors, and 1.45 (P < 0.0001) after full adjustment including adjustment for assignment to the standard or intensive treatment strategy. The last A1C showed no association with mortality in the unadjusted analysis or in models 1 and 2, but after adjustment for treatment assignment in model 3, a significant association was apparent (HR 1.14, P < 0.003). No relationships between the 1-year or 4-month decreases of A1C from baseline and subsequent mortality were found before adjustment for covariates, but model 3 demonstrated a significant relationship for the 1-year change (HR 0.85, P < 0.013). With average and last A1C, a higher on-treatment A1C value was associated with a greater risk of death. The 1-year decrease in A1C analysis in model 3 showed that a greater decrease of A1C was associated with a lower risk of death.

**Adjusted risk of all-cause mortality over the observed range of average A1C**

The relationship between average A1C and mortality was examined within the intensive and standard treatment strategies separately, as well as their interaction, using the fully adjusted regression model 3. Different relationships were apparent (P_{interaction} = 0.0007). The HR for 1% higher A1C for the intensive strategy

### Table 1—Continued

| Baseline characteristic          | Value      | HR (95% CI)     | P value | Overall P value |
|---------------------------------|------------|-----------------|---------|-----------------|
| Serum creatinine (mg/dl)        | 0.91 ± 0.23| 2.44 (1.72–3.46)| <0.0001|                 |
| Urinary albumin-to-creatinine ratio (mg/mg) |            |                 |         |                 |
| 30–<300                        | 2.501 (24.6)| 1.7 (1.39–2.09) | <0.0001|                 |
| >300                           | 673 (6.6)  | 2.9 (2.2–3.81)  | <0.0001|                 |
| <30                            | 6.998 (68.8)| 1                |         | 0.894           |
| Integrated health plan         | 4.078 (39.8)| 1.39 (1.16–1.68)| 0.0004  |                 |
| Endocrinologist or diabetologist | 5.706 (55.7)| 0.84 (0.7–1)    | 0.0556  |                 |
| Certified diabetes educator on staff at rand | 3.960 (38.6)| 0.94 (0.78–1.14)| 0.5429  |                 |
| Site size                      |            |                 |         |                 |
| <100                           | 1.583 (15.4)| 0.94 (0.72–1.24) | 0.6837  |                 |
| 100–150                        | 3.049 (29.7)| 0.97 (0.78–1.19)| 0.7385  |                 |
| >150                           | 5.619 (54.8)| 1                |         |                 |

Values are means ± SD, n (%), or HR (95% CI).

### Table 2—HRs (95% CI) from Cox proportional hazard models

| Model includes | Unadjusted | Model 1 | Model 2 | Model 3 | Model 3, intensive | Model 3 standard | Interaction P value* |
|----------------|------------|---------|---------|---------|-------------------|-----------------|----------------------|
| Average A1C    | 1.20 (1.09–1.32) | 1.20 (1.08–1.33) | 1.22 (1.10–1.36) | 1.45 (1.3–1.63) | 1.66 (1.46–1.89) | 1.14 (0.95–1.38) | 0.007                |
| P value        | 0.0002     | 0.0008  | P < 0.0001 | P < 0.0001 | P < 0.0001 | 0.17 | 0.0007               |
| Last A1C       | 1.06 (0.98–1.15) | 1.05 (0.96–1.14) | 1.07 (0.98–1.16) | 1.14 (1.05–1.25) | 1.27 (1.14–1.41) | 0.98 (0.86–1.13) | 0.0030               |
| P value        | 0.15       | 0.28    | 0.12    | 0.0026  | 0.0011  | 0.81 | 0.0030               |
| 1-year decrease of A1C | 1.02 (0.94–1.10) | 0.98 (0.87–1.10) | 0.96 (0.86–1.07) | 0.85 (0.75–0.97) | 0.86 (0.74–1.01) | 0.83 (0.71–0.97) | 0.66                  |
| P value        | 0.69       | 0.71    | 0.46    | 0.0127  | 0.06    | 0.0227 | 0.66                  |
| 4-month decrease of A1C | 1.00 (0.92–1.09) | 0.98 (0.88–1.09) | 0.97 (0.87–1.08) | 0.90 (0.79–1.01) | 0.92 (0.79–1.07) | 0.88 (0.76–1.02) | 0.61                  |
| P value        | 0.98       | 0.74    | 0.56    | 0.07    | 0.25    | 0.07  | 0.61                  |

Model 1 contains these baseline characteristics: age, sex, congestive heart failure, amputation, smoking, alcohol use, use of secretagogues, visual acuity, peripheral nerve function, Q-T interval, A1C, urinary albumin-to-creatinine ratio, and site in integrated health system. Model 2 adds assignment to blood pressure or lipid trial and treatment assignment within these, severe hypoglycemia, and weight change. Model 3 adds glycemic treatment strategy assignment. *P value for interaction of treatment assignment with the A1C relationships in model 3 is shown in the column at the right.
was 1.66 (95% CI 1.46–1.89, \( P < 0.0001 \)) and that for the standard strategy was 1.14 (0.95–1.38, \( P = 0.17 \)). These relationships for the two strategies were also examined over a wide range of updated average A1C values, using smoothed spline plots and adjusting for all covariates (Fig. 1). These curves were also clearly different for the two strategies (\( P_{\text{interaction}} = 0.0003 \)). There was marginal evidence of nonlinearity among intensive treatment participants (\( P = 0.08 \)) but stronger evidence for nonlinearity among standard treatment participants (\( P = 0.0184 \)). The curve for the intensive strategy showed the risk of mortality increasing steadily with higher average A1C in the range from 6.0 to 9.0%. In contrast, the lowest risk with the standard strategy was associated with average A1C between 7.0 and 8.0%. The estimates for these two curves were separated for A1C values from 7.0% to >9.0%, suggesting a possible higher risk for participants using the intensive strategy in this range. This observation is consistent with the increased risk of mortality associated with the intensive strategy using model 3, both without inclusion of average A1C as a covariate (HR 1.25, \( P < 0.02 \)) and when average A1C was included (HR 1.82, \( P < 0.0001 \)).

**Frequency of all-cause mortality over the range of decrease of A1C in the 1st year**

The effect of the initial decrease in A1C was further explored in an analysis shown in Fig. 2, which adjusted for the variables in model 3. With the standard strategy, death rates during the entire period of study did not vary over the range of 1-year A1C decrease. With the intensive strategy, the risk of death was similar to that with the standard strategy when moderate or large decreases in A1C occurred, but higher risk was suggested when little or no decrease in A1C followed initiation of treatment.

**CONCLUSIONS**—These post hoc analyses produced several hypothesis-generating insights. First, the 1- to 2-year delay between the initial reduction of A1C and the increase of mortality with the intensive strategy suggests that factors other than current A1C levels contributed. The broad range of average A1C values before deaths in both treatment groups also supports this view.

Second, the glycemic measure most strongly associated with death was the average A1C. Without adjustment, after adjustment for baseline factors, and after further adjustment for some postrandomization factors, a 1% greater average A1C was associated with 20, 20, and 22% increases in the risk of death. This association, not taking into consideration the glycemic treatment strategy, is similar to the 12 and 14% increments of mortality associated with 1% higher average A1C in epidemiologic analyses from other studies (6,19). In the fully adjusted analysis including glycemic treatment strategy this association was even stronger. Last A1C measurements and decreases in A1C in the 1st year of treatment showed weaker...
associations, which were significant only after adjustment for treatment assignment. A 1% higher last A1C was associated with 14% greater risk, and a 1% greater decrease in A1C from baseline in the 1st year with 15% lower risk.

Third, the relationships between average A1C and mortality differed between the treatment strategies. Using the fully adjusted proportional hazards regression model, higher average A1C during use of the intensive strategy was strongly associated with greater mortality (66% greater for 1% higher, \( P < 0.0001 \)). To better understand possible differences introduced by treatment assignment, we also considered these relationships when displayed as smoothed spline plots over a range of average A1C.

With the intensive strategy, the risk of death increased continuously from 6.0 to 9.0% average A1C, whereas the curve for the standard strategy was distinctly nonlinear. The excess risk associated with intensive glycemic treatment occurred among those participants whose average A1C, contrary to the intent of the strategy, was >7%.

These observations must be interpreted cautiously, because the analyses were not defined before treatment was started, the period of follow-up was shorter than planned, and the results could have been influenced by many post-randomization factors. However, they are relevant to the debate about which targets for glycemic control should be advised for patients with type 2 diabetes and evidence of high cardiovascular risk. These findings confirm the earlier report warning of increased risk of death associated with the intensive treatment strategy in ACCORD (11), but they suggest that low A1C is unlikely to be a primary mediator of this risk. They do not support the hypothesis that overly rapid reduction of A1C from high levels increases risk of death. In fact, the opposite relationship was observed. Participants who were unable to reduce A1C after initiation of the intensive strategy and continued to have average A1C >7% seemed to be at greater risk than those with average A1C <7% using the same strategy or than those with A1C >7% using a standard strategy.

At present, the factors that lead to increased risk associated with A1C averaging >7% during use of an intensive treatment strategy remain unknown. Characteristics of the participants that were not measured may be involved. Among these are behavioral issues such as lack of adherence to medical advice, depression or other psychiatric conditions, abnormal cognitive function, and social or financial crises. Emergence of serious medical problems other than diabetes itself might interfere with treatment of hyperglycemia and at the same time increase the risk of mortality. Finally, the potential effects of hypoglycemia, weight gain, and various drugs require further attention. We also await data on ocular, renal, and cognitive function, as well as on mortality and cardiovascular events during longer follow-up, which may contribute to the balance of risks versus benefits.
In summary, these analyses confirm that excess risk of all-cause mortality was associated with the intensive glycemic treatment strategy used in the ACCORD trial. They suggest that factors associated with A1C persisting at >7%, rather than lower A1C, were associated with this risk. They are also consistent with other epidemiological analyses, which suggest a continuous gradient of risk of mortality, increasing from lower to higher A1C levels.

Acknowledgments—This work was supported by contracts (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA-Y1-HC-9035, and IAA-Y1-HC-1010) from the National Heart, Lung, and Blood Institute; by other components of the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Eye Institute; by the Centers for Disease Control and Prevention; and by General Clinical Research Centers. The following companies provided study medications, equipment, or supplies: Abbott Laboratories, Amylin Pharmaceutical, AstraZeneca, Bayer HealthCare, Closer Healthcare, GlaxoSmithKline, King Pharmaceuticals, Merck, Novartis, Novo Nordisk, Omron Healthcare, Sanofi-Aventis, and Schering-Plough.

M.C.R. has received honoraria from Amylin Pharmaceuticals, Eli Lilly and Company, and sanofi-aventis; has been a paid consultant for Amylin Pharmaceuticals, Eli Lilly and Company, Pfizer, Valeritas, and sanofi-aventis; and has received research support from Amylin Pharmaceuticals, Eli Lilly and Company, and sanofi-aventis. D.J.B. holds stock in Novo Nordisk, Eli Lilly and Company, and GlaxoSmithKline. J.B.B. is a consultant and investigator for most pharmaceutical and device manufacturers with an interest in diabetes under contract with the University of North Carolina. These provide no direct financial benefit to him. D.C.G. is deputy editor of the American Medical Association Archives of Internal Medicine; has received honoraria for speaking engagements from The Institute for Diabetes, Obesity, and Cardiovascular Disease; and the Consortium for Southeastern Hypertension Control; is a consultant and chair of a Data Safety Monitoring Board for the National Heart, Lung, and Blood Institute-funded initiative for Johns Hopkins University; has acted as principal investigator of clinical sites for two research grants presented by Merck to Wake Forest University School of Medicine; has acted as expert witness on product liability issues for Scientific Evidence, Inc. D.M.K. has received research support from National Institutes of Health-Health National Heart, Lung, and Blood Institute, Abbott Diabetes Care, Amylin Pharmaceuticals, Dexcom, Eli Lilly and Company, Merck, Nova Nordisk, Roche, and sanofi-aventis; has been an unpaid consultant or scientific advisor for Amylin Pharmaceuticals, Daiichi-Sankyo, Eli Lilly and Company, HealthPartners, Intarcia, Merck, Roche, Takeda, and the United Health Group. K.L.M. benefits from a research grant from Bristol-Myers Squibb presented to the HealthPartners Research Foundation.

No other potential conflicts of interest relevant to this article were reported.

The Steering Committee of the Investigators, the Coordinating Center, and the National Heart, Lung, and Blood Institute Project Office of ACCORD all had roles in the design and management of the trial and in developing procedures for analysis. The companies that donated study medications, equipment, or supplies had no role in collecting or analyzing the data or drafting the manuscript.

Parts of this study were presented in abstract form at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5–9 June 2009.

Two additional members of the writing group, David Kendall and George Grunberger, could not be included as authors; we thank them for their contributions to developing this article.

References

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035–2038

2. Stamler J, Vaccaro A, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–444

3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234

4. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;21:1167–1172

5. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;41:1423–1448

6. Stratton IM, Adler AI, Neil HA, Mathias DR, Manley S, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412

7. Selvin E, Marmotopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421–431

8. Goff DC, Gerstein HC, Ginsberg HN, Cushman WE, Margolis KL, Byington RP, Buse JB, Genuith S, Probstfield JL, Simons-Morton DG, ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(Suppl.):4–20

9. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(Suppl.):21i–33i

10. Gerstein HC, Riddle MC, Kendall DM, Cobben RM, Goland R, Fungmlos MN, Kirk JK, Hamilton B, Ismail-Beigi F, Fenney P, ACCORD Study Group. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(Suppl.):34i–43i

11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Golf DC Jr, Bigger JT, Buse JB, Cushman WC, Genuith S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559

12. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630–2633

13. Hirsch IB. Piecing the puzzle together: ACCORDing to whom? J Clin Endocrinol Metab 2008;93:1161–1163

14. Sklery J, Bergensdal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientifi statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2008;31:187–192

15. Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN, ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99(Suppl.):43i–55i

16. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PJ, O’Connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL, ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes
AIC and mortality in ACCORD

17. Eiler PH, Marx BD. Flexible smoothing with B-splines and penalties. Stat Sci 1996;11:89–121
18. Hurvich CM, Siminoff JS, Tsai C-L. Smoothing parameter selection in non-parametric regression using an improved Akaike information criterion. J R Stat Soc Ser B 1998;60:271–293
19. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S, HOPE Investigators. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiologic analysis. Diabetologia 2005;48:1749–1755